StockMacro
Menu

Madrigal Pharmaceuticals

MDGL on XNAS, Madrigal Pharmaceuticals, Inc.

Measures activity, not value. Not investment advice.

Latest quarter (Jul 2026)

+50%

-160.6 pts vs its 3-year median

Sharp changes

6

quarterly revenue change, quarterly capital spending jump

Window

What usually follows Revenue growth was not followed by a clear share-price difference over the next 6 months. No relationship found How we measured it

Median revenue growth on a year earlier: +50% in the quarter from 1 Jul 2026 (3-year median +211%)

10-Q and 10-K figures, by the quarter they describe. Dashed: 3-year median.

See the numbers
Quarter of Jul 2026: +50%
Quarter of Apr 2026: +71%
Quarter of Jan 2026: +127%
Quarter of Oct 2025: +211%
Quarter of Jul 2025: +362%
Quarter of Apr 2025: +1354%

What the numbers say

  • Median revenue growth on a year earlier: +50% in the quarter from 1 Jul 2026 (3-year median +211%).
  • 6 sharp changes in all loaded history (quarterly revenue change, quarterly capital spending jump).
  • Median growth on a year earlier, latest complete quarter: the largest is Inventory, +77%.
Median growth on a year earlier, latest complete quarter: the largest is Inventory, +77%
See the numbers
Inventory+77%
R&D expense-59%
Revenue+50%

Every measure from this source

5 years, by the period each figure describes

Revenue (quarter). $1.4B in the last 12 months, +93% on the year before.
Capital spending (quarter). $12.0M in the last 12 months, +6069% on the year before.
R&D expense (quarter). $387.9M in the last 12 months, +30% on the year before.
Inventory (quarter end). $122.6M in the latest period, +77% on a year earlier.
Revenue (fiscal year). $958.4M in the last 12 months, +432% on the year before.
Capital spending (fiscal year). $467K in the last 12 months, -68% on the year before.
R&D expense (fiscal year). $388.5M in the last 12 months, +64% on the year before.
Shares outstanding. 23.1M in the latest period, +3.7% on a year earlier.

Sharp changes

6 in all loaded history, strongest first

Madrigal Pharmaceuticals reported revenue of $212.8M for the quarter ended 30 Jun 2025, 15× the same quarter last year.

Quarterly revenue change, became public on 7 Aug 2025

Same quarter last year: $14.6M; its normal quarter is $7.3M.

See the evidence
This period
$212.8M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$7.3M
Typical spread (median absolute deviation)
$7.3M
How far from its usual level
+18.9
Same quarter last year
$14.6M
History used
2,648 days
2023-06-30: $02023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M2024-09-30: $62.2M2024-12-31: $103.3M2025-03-31: $137.2M2025-06-30: $212.8M
the quarter ended 30 Jun 20258 earlier quartersnormal: $7.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Madrigal Pharmaceuticals reported revenue of $137.2M for the quarter ended 31 Mar 2025, against none in the same quarter last year.

Quarterly revenue change, became public on 6 May 2025

See the evidence
This period
$137.2M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+137.2
Same quarter last year
$0
History used
2,557 days
2023-03-31: $02023-06-30: $02023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M2024-09-30: $62.2M2024-12-31: $103.3M2025-03-31: $137.2M
the quarter ended 31 Mar 20258 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Madrigal Pharmaceuticals reported revenue of $103.3M for the quarter ended 31 Dec 2024, against none in the same quarter last year.

Quarterly revenue change, became public on 4 Mar 2025

See the evidence
This period
$103.3M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+103.3
Same quarter last year
$0
History used
2,467 days
2022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M2024-09-30: $62.2M2024-12-31: $103.3M
the quarter ended 31 Dec 20248 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Madrigal Pharmaceuticals reported revenue of $62.2M for the quarter ended 30 Sep 2024, against none in the same quarter last year.

Quarterly revenue change, became public on 5 Nov 2024

See the evidence
This period
$62.2M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+62.2
Same quarter last year
$0
History used
2,375 days
2022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M2024-09-30: $62.2M
the quarter ended 30 Sep 20248 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Madrigal Pharmaceuticals reported revenue of $14.6M for the quarter ended 30 Jun 2024, against none in the same quarter last year.

Quarterly revenue change, became public on 13 Aug 2024

See the evidence
This period
$14.6M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+14.6
Same quarter last year
$0
History used
2,283 days
2022-06-30: $02022-09-30: $02022-12-31: $02023-03-31: $02023-06-30: $02023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M
the quarter ended 30 Jun 20248 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Madrigal Pharmaceuticals reported revenue of $287.3M for the quarter ended 30 Sep 2025, 4.6× the same quarter last year.

Quarterly revenue change, became public on 6 Nov 2025

Same quarter last year: $62.2M; its normal quarter is $38.4M.

See the evidence
This period
$287.3M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$38.4M
Typical spread (median absolute deviation)
$38.4M
How far from its usual level
+4.4
Same quarter last year
$62.2M
History used
2,740 days
2023-09-30: $02023-12-31: $02024-03-31: $02024-06-30: $14.6M2024-09-30: $62.2M2024-12-31: $103.3M2025-03-31: $137.2M2025-06-30: $212.8M2025-09-30: $287.3M
the quarter ended 30 Sep 20258 earlier quartersnormal: $38.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

The records

One row per company, data through 1 Nov 2026

Showing 1 to 1 of 1.
CompanySectorLatest quartervs year before
Madrigal PharmaceuticalsHealth Care$431.3M